MX006 / Myricx Pharma - LARVOL DELTA

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3 (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Myricx Pharma Limited

First-in-human • New P1 trial • Oncology • Prostate Cancer • Solid Tumor • CD276